Global Sanfilippo A Market, By Diagnosis (GAG analysis, Activity Assay, Genomic DNA Sequencing, and Others), Treatment (Drugs, Enzyme Replacement Therapy, Gene Therapy, Genistein, and Others), Mode of Administration (Injectable, Oral, and Others), End User (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2030.
Sanfilippo A Market Analysis and Size
The incidence of sanfilippo A varies depending on the population and geographical location. Sanfilippo A an autosomal recessive disorder, meaning that both parents must carry a mutated gene to pass it on to their child is estimated that this disorder is approximately 1 in 100,000 to 1 in 300,000 live births.
Data Bridge Market Research analyses that the sanfilippo A market, which was USD 9,750.00 million in 2022, would rocket up to USD 19,859.39 million by 2030 and is expected to undergo a CAGR of 9.3% during the forecast period. “Genomic DNA Sequencing” dominates the diagnosis segment of the Sanfilippo A market owing to the growing demand for better treatment and diagnosis methods. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Sanfilippo A Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
By Diagnosis (GAG analysis, Activity Assay, Genomic DNA Sequencing, and Others), Treatment (Drugs, Enzyme Replacement Therapy, Gene Therapy, Genistein, and Others), Mode of Administration (Injectable, Oral, and Others), End User (Hospitals, Homecare, Specialty Clinics, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of Middle East and Africa.
|
|
Market Players Covered
|
Amgen Inc (U.S.), Alkem Labs (India), LUPIN (India), Hope Pharmaceuticals (U.S.), Sanifit (Spain), BSN medical (Germany), Sun Pharmaceutical Industries Ltd (India), Cipla Inc (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Zydus Cadila (India)
|
|
Market Opportunities
|
|
Market Definition
Sanfilippo syndrome, or mucopolysaccharidosis (MPS) type III, is one of five autosomal recessive, neurodegenerative lysosomal storage disorders (MPS IIIA to MPS IIIE). The disorder's symptoms are generally caused by the deficiency of enzymes exclusively involved in heparin sulfate degradation. Degeneration of the central nervous system, commencing during childhood and resulting in mental retardation and hyperactivity, are some of the primary characteristics of MPS III.
Global Sanfilippo A Market Dynamics
Drivers
- Supportive Care and Symptom Management
While there is no cure for sanfilippo A, supportive care and symptom management are crucial in improving the quality of life for individuals with the condition. The demand for supportive care products, therapies, and interventions drives the market's growth.
- Patient Advocacy and Support
Patient advocacy groups and foundations are crucial in raising awareness, supporting affected individuals and their families, and funding research initiatives. The efforts of these organizations contribute to the development and growth of the Sanfilippo A market by driving research, increasing public knowledge, and providing support networks.
Opportunities
- Improving Research and Development Activities
The sanfilippo A market offers significant opportunities for research and development efforts. Advancements in understanding the underlying mechanisms of the disease, exploring new therapeutic approaches, and identifying potential targets for intervention can lead to the development of innovative treatments. Continued investment in research can unlock new opportunities for disease management and potentially a cure.
- Improved Diagnosis and Newborn Screening
Advances in diagnostic techniques and newborn screening programs offer opportunities to identify Sanfilippo A at an early stage. Early diagnosis allows for timely intervention and management, potentially improving outcomes for affected individuals. Expanded implementation of newborn screening programs can increase the identification of newborns with Sanfilippo A, enabling early intervention.
Restraints/Challenges
- Lack of Treatment Options
Currently, there is no approved cure for Sanfilippo A. The limited availability of effective treatment options leaves patients and their families with few choices to manage the disease. This lack of treatment options highlights the need for further research and development efforts.
- Reimbursement and Affordability
The high costs associated with rare disease treatments can pose challenges regarding reimbursement and affordability. The limited patient population and high development costs can result in expensive treatments, making it difficult for patients to access them. Ensuring adequate reimbursement and affordability of sanfilippo A treatments is a significant challenge.
This sanfilippo A market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In December 2022, Orchard Therapeutics announced positive interim data from a clinical trial of their investigational gene therapy OTL-201 for Sanfilippo syndrome type A. The therapy showed improvements in neurocognitive and behavior measures in treated patients
- In February 2021, Abeona Therapeutics was developing an investigational gene therapy called ABO-101 for Sanfilippo syndrome type A. They recently announced positive results from their Phase 1/2 clinical trial, showing improvements in neurocognitive development and reduced disease progression.
Global Sanfilippo A Market Scope
The sanfilippo A market is segmented on the basis of diagnosis, treatment, mode of administration, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- GAG analysis
- Activity Assay
- Genomic DNA Sequencing
- Others
Treatment
- Drugs
- Enzyme Replacement Therapy
- Gene Therapy
- Genistein
- Others
Mode of Administration
- Injectable
- Oral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Global Sanfilippo A Market Regional Analysis/Insights
The global Sanfilippo A market is analysed and market size insights and trends are provided by country, diagnosis, treatment, mode of administration, and end-users as referenced above.
The countries covered in the Sanfilippo A market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of Middle East and Africa.
North America is expected to dominate the market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having Sanfilippo syndrome, or mucopolysaccharidosis (MPS) type III.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for treatment and diagnosis, the large population pool, and the increasing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The sanfilippo A market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the sanfilippo A market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Sanfilippo A market.
Competitive Landscape and Sanfilippo A Market Share Analysis
The sanfilippo A market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Sanfilippo A market.
Some of the major players operating in the sanfilippo A market are:
- Amgen Inc (U.S.)
- Alkem Labs (India)
- LUPIN (India)
- Hope Pharmaceuticals (U.S.)
- Sanifit (Spain)
- BSN medical (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Cipla Inc (India)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Cadila (India)
SKU-